Evaluation the effects of Hydroxychloroquine administration for COVID-19 prophylaxis

Phase 3

Recruiting

• Conditions: COVID-19 pneumonia.; COVID-19, virus not identified; U07.2

• Registration Number: IRCT20130917014693N10
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Age over 18 years old
Close contact with COVID-19 patient at least in past 4 days
sign the informed consent form to participate in study

Exclusion Criteria

Pervious case of COVID-19
Current case of COVID-19
Presenting influenza like symptoms (fever, cough, and sore throat) in last 30 days
Travel history in last 14 days
Lactation and pregnancy
History of arrhythmia
Drug allergy history
Favism history
Chronic liver disease
Chronic kidney disease
Retinopathy history
Weight under 40 kg
Patients who are receiving arritmogenica medicines

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Questionnaire.;Dyspnea. Timepoint: Daily. Method of measurement: Questionnaire.;Sore throat. Timepoint: Daily. Method of measurement: Questionnaire.;Myalgia. Timepoint: Daily. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Disease severity. Timepoint: At end of the study. Method of measurement: Clinical scoring for disease severity.;Death. Timepoint: Day 7, day 14, and day 28. Method of measurement: Observation.;Adverse reactions. Timepoint: Daily. Method of measurement: Observation.